Reports Q4 revenue $7.283M, consensus $2.07M. "Werewolf enters 2023 with considerable momentum following exceptional execution across our Company in 2022. In particular, we initiated clinical trials for our two lead INDUKINE programs, WTX-124 and WTX-330, and also advanced our newest IL-21 INDUKINE pipeline candidate WTX-712," said Daniel Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. "This year we anticipate multiple catalysts as we progress our two clinical stage programs, WTX-124 and WTX-330, through first in human testing and expect to share initial clinical data on the safety, tolerability, and preliminary efficacy of WTX-124 in the fourth quarter. Also of note, we have extended our cash runway beyond previous guidance and through at least the fourth quarter of 2024, which provides us the opportunity to reach multiple potential value creating milestones."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HOWL:
- Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
- Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
- Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
- Werewolf Therapeutics doses first patient in Phase 1 study of WTX-330